Hi {{lead.First Name:default=edit me}},

Leukopaks (leukocyte-enriched apheresis products) from patients with confirmed disease or healthy individuals provide you with ~10 billion PBMCs in a single donation, circumventing the inherent variability of multiple donors. When paired with relevant medical data, they represent ideal research tools for developing and validating biomarker assays, particularly in support of cell & gene therapies, for which leukopaks are the final drug product.

Sanguine manages biospecimen procurement from 70,000+ research-ready patient donors across 100+ disease conditions (35 qualified for apheresis). Please check out our leukopaks page to learn how these products can accelerate your diagnostics development program or hit reply to contact me directly.

Warm regards,

Brian Neman
CEO and Co-Founder
Sanguine Biosciences | Massachusetts